Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals
Brian Grunau, David A. Goldfarb, Michael Asamoah-Boaheng, et al.
JAMA (2021) Vol. 327, Iss. 3, pp. 279-279
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Alexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch, et al.
Science (2022) Vol. 375, Iss. 6581, pp. 678-680
Open Access | Times Cited: 340
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
John E. Bowen, Amin Addetia, Ha V. Dang, et al.
Science (2022) Vol. 377, Iss. 6608, pp. 890-894
Open Access | Times Cited: 174
Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
Laura Pérez‐Alós, José Juan Almagro Armenteros, Johannes Roth Madsen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 163
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Ali Zhang, Hannah D. Stacey, Michael R. D’Agostino, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 6, pp. 381-396
Open Access | Times Cited: 126
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
David J. Sullivan, Massimo Franchini, Michael J. Joyner, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 78
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Shô Miyamoto, Takeshi Arashiro, Yu Adachi, et al.
Med (2022) Vol. 3, Iss. 4, pp. 249-261.e4
Open Access | Times Cited: 69
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)
Takeshi Arashiro, Yuzo Arima, Hirokazu Muraoka, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e108-e115
Open Access | Times Cited: 56
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
Debashree Chatterjee, Alexandra Tauzin, Lorie Marchitto, et al.
Cell Reports (2022) Vol. 38, Iss. 9, pp. 110429-110429
Open Access | Times Cited: 55
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases
Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N. Albach, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 6, pp. 881-888
Open Access | Times Cited: 46
An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants
Timothy A. Bates, Hans C. Leier, Savannah K. McBride, et al.
JCI Insight (2023) Vol. 8, Iss. 5
Open Access | Times Cited: 33
Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study
Madhumita Shrotri, Ellen Fragaszy, Vincent Nguyen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals
Brian Grunau, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 29
Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity
Michael Asamoah-Boaheng, David A. Goldfarb, Martin A. Prusinkiewicz, et al.
Cureus (2023)
Open Access | Times Cited: 15
Durable immune responses after BNT162b2 vaccination in home-dwelling old adults
Lena Hansen, Karl A. Brokstad, Amit Bansal, et al.
Vaccine X (2023) Vol. 13, pp. 100262-100262
Open Access | Times Cited: 13
Immune imprinting and vaccination interval underly XBB.1.5 monovalent vaccine immunogenicity
Xammy Nguyenla, Timothy A. Bates, Mila Trank-Greene, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters
J. Ahmed, Samantha J. Krosta, M. Reimer, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Shô Miyamoto, Takeshi Arashiro, Yu Adachi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 20
Development of antibody resistance in emerging mutant strains of SARS CoV‐2: Impediment for COVID‐19 vaccines
Narasimha M. Beeraka, Olga Sukocheva, Elena Lukina, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 5
Open Access | Times Cited: 20
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease
Leonie Maria Frommert, Amanthi Nadira Arumahandi de Silva, Jan Zernicke, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002650-e002650
Open Access | Times Cited: 20
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
Manon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Cell Reports (2022) Vol. 39, Iss. 13, pp. 111013-111013
Open Access | Times Cited: 19
An mRNA vaccine against rabies provides strong and durable protection in mice
Miao Li, Enyue Fang, Yunpeng Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Alina Seidel, Michelle Zanoni, Rüdiger Groß, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
Alexandre Nicolas, Gérémy Sannier, Mathieu Dubé, et al.
iScience (2022) Vol. 26, Iss. 1, pp. 105904-105904
Open Access | Times Cited: 17
Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
Zitta Barrella Harboe, Sebastian Rask Hamm, Laura Pérez‐Alós, et al.
BMJ Open Respiratory Research (2022) Vol. 9, Iss. 1, pp. e001268-e001268
Open Access | Times Cited: 16
The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study
N. Almeida, Ian Schiller, Danbing Ke, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top